课题基金 / 基金详情

Enhanced immunogenicity and protection study of lipid modified protein vaccine candidates of Nontypeable Haemophilus influenzae

Enhanced immunogenicity and protection study of lipid modified protein vaccine candidates of Nontypeable Haemophilus influenzae
不可分型流感嗜血杆菌脂质修饰蛋白候选疫苗的增强免疫原性和保护性研究
批准号:
10245160
负责人:
Ravinder Kaur
金额:
$20.0万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-08-21 至 2023-07-31

项目摘要

项目成果

Ravinder Kaur的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Abstract: In the conjugate vaccine era, Nontypeable Haemophilus influenzae (NTHi) has become the leading cause of acute otitis media (AOM), recurrent AOM, acute sinusitis and conjunctivitis in children and adults and acute exacerbations of chronic obstructive pulmonary disease (COPD) in adults. There is need to develop a vaccine against NTHi. Various vaccine candidates have been explored but still there is need for enhancement of antibody and Th17 immunity response for NTHi vaccines that will help prevent nasopharyngeal colonization and infection. In this project we will compare immunogenicity of recombinant proteins P6 and OMP26 and their fusion constructs in their lipidated and non-lipidated form in a mouse coinfection model of NTHi-AOM, we developed. Two proteins were selected based on their different function and considering P6 is naturally lipidated and native OMP26 is not but is known to induce Th17 immunity. We will test our hypothesis that lipidated protein antigens elicit higher blood and mucosal antibody levels as well as Th17 immune response (via toll-like receptor 2 activation) than non lipidated proteins. Lipidated protein antigens will elicit greater reduction in ear and nasal bacterial loads compared to nonlipidated antigens against NTHi. The contribution and mechanism of antibody mediated and TH17-mediated immunity in protection against NTHi will be compared in infant and adult mice as well as in TLR2-knock out mice using lipidated, nonlipidated and fusion constructs of vaccine candidates P6 and OMP26. We will test whether lipidated proteins produce a more robust IL-17A response from memory Th17 cells in the nasopharynx that helps traffic neutrophils and show enhanced NTHi clearance compared to nonlipidated protein antigens. Overall, the proposed studies will significantly advance our understanding of enhanced immunogenicity of recombinant proteins and molecular mechanisms underlying the lipidation regulation of TLR-2 dependent Th17- immunity in NTHi vaccine development.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Vaccine target and carrier molecule nontypeable Haemophilus influenzae protein D dimerizes like the close Escherichia coli GlpQ homolog but unlike other known homolog dimers.
疫苗靶标和载体分子不可分型流感嗜血杆菌蛋白 D 像接近的大肠杆菌 GlpQ 同源物一样二聚化,但与其他已知的同源物二聚体不同。
DOI: 10.1002/prot.26418
发表时间: 2023
期刊: Proteins
影响因子: 2.9
作者: [Jones,SethP, Cook,KaliH, Holmquist,MelodyL, Almekinder,LiamJ, Delaney,AnnieM, Charles,Ryhl, Labbe,Natalie, Perdue,Janai, Jackson,Niaya, Pichichero,MichaelE, Kaur,Ravinder, Michel,LeaV, Gleghorn,MichaelL]
通讯作者: Gleghorn,MichaelL
DOI: 10.1002/2211-5463.13498
发表时间: 2022-12
期刊: FEBS OPEN BIO
影响因子: 2.6
作者: [Michel, Lea V., Kaur, Ravinder, Gleghorn, Michael L., Holmquist, Melody, Pryharski, Karin, Perdue, Janai, Jones, Seth P., Jackson, Niaya, Pilo, Isabelle, Kasper, Anna, Labbe, Natalie, Pichichero, Michael]
通讯作者: Pichichero, Michael
DOI: 10.1016/j.jbc.2023.105031
发表时间: 2023-08
期刊: JOURNAL OF BIOLOGICAL CHEMISTRY
影响因子: 4.8
作者: [Kaur, Ravinder, Mangiafesto, Jill, Pryharski, Karin, Rasam, Sailee, Zagursky, Robert, Pichichero, Michael]
通讯作者: Pichichero, Michael
Enhanced immunogenicity and protection study of lipid modified protein vaccine candidates of Nontypeable Haemophilus influenzae
  • 批准号:
    10042550
  • 项目类别:
  • 资助金额:
    $24.0万
  • 财政年份:
    2020
  • 负责人:
    Ravinder Kaur
  • 依托单位:
Antibody & Cellular Immune responses in children after 2 vs 3 doses and pre vs post booster of PCV13 Vaccine
  • 批准号:
    9316990
  • 项目类别:
  • 资助金额:
    $8.48万
  • 财政年份:
    2017
  • 负责人:
    Ravinder Kaur
  • 依托单位:
海外基金